Find oncology molecular diagnostic tests

Browse curated oncology molecular diagnostic test profiles with intended use, specimen, modality, assay-version context, study populations and source-linked evidence.

  • 4Kscore Test — Serum or plasma multi-analyte kallikrein test with an algorithmic score used to aid prostate-biopsy decisions and detection of aggressive prostate cancer.
  • Abbott RealTime IDH1 — U.S. real-time PCR assay for source-scoped IDH1 mutation testing in AML and myeloid malignancy treatment-selection contexts.
  • Abbott RealTime IDH2 — U.S. real-time PCR assay for source-scoped IDH2 mutation testing in acute myeloid leukemia.
  • Afirma GSC — RNA-expression genomic classifier used as a diagnostic aid for cytologically indeterminate thyroid nodules.
  • AlphaLiquid 100 — 118-gene blood-based targeted comprehensive genomic profiling assay for solid tumors.
  • AlphaLiquid HRR — Blood-based targeted NGS assay for homologous-recombination-repair genomic profiling in solid tumors.
  • AlphaSolid 100 — Tissue-biopsy targeted comprehensive genomic profiling assay for solid tumors.
  • Altera — Tumor comprehensive genomic profiling using whole-exome and whole-transcriptome sequencing.
  • AmoyDx Pan Lung Cancer PCR Panel — Multiplex real-time PCR panel for actionable DNA alterations and RNA fusions across 11 lung-cancer genes.
  • APEX Tissue — 58-gene DNA/RNA targeted NGS panel for molecular profiling of solid tumors.
  • Avantect Ovarian Cancer Test — Cell-free DNA blood LDT intended as an aid to earlier ovarian-cancer detection in women at elevated risk.
  • Avantect Pancreatic Cancer Test — Blood-based multi-analyte, multiomic test intended to support earlier pancreatic cancer detection in elevated-risk patients.
  • Bladder EpiCheck — Urine DNA methylation test for non-invasive monitoring of bladder cancer recurrence; jurisdiction-specific indications remain separate.
  • BluePrint — 80-gene RNA-expression assay for molecular subtype classification in breast cancer.
  • Blueprint Genetics Comprehensive Hereditary Cancer Panel — 160-gene germline panel for inherited cancer susceptibility, including selected non-coding variants.
  • BRACAnalysis CDx — Germline BRCA1/2 companion diagnostic used for treatment selection across specified BRCA-associated cancer indications.
  • BRCAplus — Guideline-based germline hereditary breast cancer panel.
  • Breast Cancer Index — PCR-based breast tumor gene-expression LDT providing distant-recurrence risk and likelihood of benefit from extended endocrine therapy.
  • CanAssist Breast — IHC- and clinicopathology-based prognostic test estimating five-year distant recurrence risk in early-stage breast cancer.
  • CanCatch Custom — Tumor-informed personalized ctDNA MRD approach using WES baseline profiling and patient-specific mutation tracking.
  • CancerDetect — Tissue-informed personalized molecular residual disease and recurrence-monitoring assay for solid tumors.
  • CancerDetect Oral & Throat — Saliva-based laboratory-developed molecular test used as a diagnostic aid for oral and throat cancer signals; not FDA-cleared or approved.
  • CancerFind — Blood-based multi-cancer early detection assay using methylation, copy-number and fragmentomic features.
  • CancerFusionRx — RNA sequencing service for detection of clinically relevant fusion transcripts in solid tumors.
  • Cancerguard — Multi-cancer early detection laboratory-developed test for adults 50–84; breast/prostate screening and precancer detection are outside the documented current use.
  • CancerNext — Guideline-based germline hereditary cancer panel.
  • CancerNext-Expanded — Germline hereditary-cancer panel; current vendor page reports 78 genes while recent official 77-gene materials require explicit version separation.
  • CancerPrecision — Tumor-normal targeted sequencing service for comprehensive molecular profiling of solid tumors.
  • CancerTYPE ID — 92-gene RT-PCR molecular classifier for difficult-to-diagnose metastatic tumors and tissue of origin.
  • CancerVision — Tumor-normal whole-genome sequencing service for comprehensive genomic profiling of solid tumors, with a plasma-based alternative when clinically applicable.
  • CancerVista — ctDNA liquid-biopsy in-house IVD for MRD detection, recurrence surveillance and therapy monitoring across solid tumors.
  • CanScan — Blood-based multi-cancer early detection test using low-depth WGS and AI integration of fragmentomic, genomic and inferred epigenomic cfDNA features.
  • Caris Assure — Whole-blood comprehensive molecular profiling for advanced solid tumors.
  • Caris ChromoSeq — Whole-genome/transcriptome profiling for diagnosed or suspected myeloid malignancies.
  • Caris Detect — Blood-based multi-cancer early detection LDT using whole-genome and whole-transcriptome sequencing with AI.
  • CeGaT Hereditary Tumor Syndromes — Germline hereditary tumor-syndrome testing based on CeGaT ExomeXtra with regularly updated cancer-predisposition gene sets.
  • clonoSEQ — NGS-based clonotype assay for measurable/minimal residual disease assessment in lymphoid malignancies, with disease- and specimen-specific FDA-cleared contexts and additional LDT uses.
  • cobas EGFR Mutation Test v2 — FDA-approved real-time PCR EGFR companion diagnostic for NSCLC.
  • Cologuard — Stool-based colorectal cancer screening test for average-risk adults.
  • Cologuard Plus — Prescription multitarget stool-based colorectal cancer screening test for average-risk adults age 45 years or older.
  • ColoHealth — Blood-based methylated SEPT9 colorectal cancer testing family; current ColoHealth Direct LDT and historical FDA device lineage are modeled separately.
  • Color Hereditary Cancer Genetic Test — Current 29-gene germline hereditary cancer susceptibility test offered through Color Health.
  • ColoScape — Multiplex plasma cfDNA mutation-and-methylation assay used in colorectal cancer screening-triage and diagnostic-aid contexts.
  • ColoSense — FDA-approved qualitative stool RNA and occult-hemoglobin colorectal cancer screening test for average-risk adults age 45 years or older.
  • COLOTECT CRC Screening — Stool-based colorectal cancer screening test combining DNA methylation and fecal occult blood detection in the current 3.0 configuration.
  • COMPASS Tissue — 1021-gene comprehensive genomic profiling assay for solid tumors.
  • Confirm mdx — PCR-based DNA methylation test performed on prior negative prostate-biopsy tissue to estimate the likelihood of occult clinically significant prostate cancer and inform repeat-biopsy decisions.
  • Cxbladder Detect — Urine mRNA biomarker test used as a diagnostic aid in urothelial cancer assessment.
  • Cxbladder Monitor — Urine mRNA biomarker test for surveillance and recurrence monitoring in bladder cancer.
  • Cxbladder Triage Plus — Urine molecular test combining gene-expression biomarkers with DNA variants for risk stratification in urothelial cancer evaluation.
  • DCISionRT — Breast-tissue biomarker test combining protein measurements with clinicopathologic factors to support risk assessment and radiation-treatment decisions in ductal carcinoma in situ.
  • Decipher Bladder — Gene-expression genomic classifier for prognosis and treatment decision support in bladder cancer.
  • Decipher Prostate — 22-gene prostate-cancer genomic classifier used for prognostic and treatment-decision risk assessment.
  • DecisionDx-Melanoma — Gene-expression profile for risk stratification and management guidance in stage I-III cutaneous melanoma.
  • DecisionDx-SCC — 40-gene expression profile with clinicopathologic integration for metastatic-risk stratification in high-risk cutaneous SCC.
  • DecisionDx-UM — Gene-expression prognostic classifier for metastatic risk in uveal melanoma.
  • EarlyTect Bladder Cancer — Urine DNA methylation test using methylated PENK as an aid in urothelial cancer detection.
  • EarlyTect Colon Cancer — Stool DNA methylation test using methylated SDC2 as an aid in colorectal cancer detection.
  • EasyM — Blood-based multiple myeloma MRD monitoring test using clonotypic peptide mass spectrometry to track M-protein.
  • Empower Hereditary Cancer Test — Germline multigene hereditary-cancer test using blood or saliva to assess inherited cancer risk.
  • EndoPredict — Gene-expression prognostic test for recurrence risk in early-stage HR-positive/HER2-negative breast cancer.
  • EPISEEK — Blood-based multi-cancer early detection LDT analyzing abnormal DNA methylation signals associated with more than 60 cancer types.
  • EpiSwitch PSE — Blood-based 3D-genomics test used with PSA to assess current likelihood of prostate cancer.
  • ExoDx Prostate — Non-DRE urine exosome RNA test providing a risk score for clinically significant prostate cancer to inform biopsy decisions.
  • FirstLook Lung — Blood-based cfDNA fragmentomics laboratory-developed test used as an adjunct in the lung-cancer screening pathway; not a replacement for LDCT.
  • Foresight CLARITY — Ultra-sensitive ctDNA molecular residual disease assay using PhasED-Seq phased-variant detection, with strong current use in B-cell lymphoma clinical programs.
  • FoundationOne CDx — Tissue-based comprehensive genomic profiling and indication-specific companion diagnostic for solid tumors.
  • FoundationOne Germline — 50-gene germline hereditary-cancer panel for inherited cancer susceptibility across multiple hereditary cancer syndromes.
  • FoundationOne Germline More — 154-gene expanded germline hereditary-cancer panel for inherited cancer susceptibility.
  • FoundationOne Heme — DNA/RNA comprehensive genomic profiling LDT for hematologic neoplasms and other source-defined indications.
  • FoundationOne Liquid CDx — Blood-based 324-gene comprehensive genomic profiling and companion-diagnostic test for advanced solid tumors. Regulatory claims are PMA-, supplement-, biomarker-, therapy- and indication-scoped.
  • FoundationOne MRD — Tissue-informed ctDNA MRD assay for stage II-III breast cancer using tumor WGS and multiplex dPCR.
  • FoundationOne RNA — 318-gene RNA sequencing LDT add-on for fusion and rearrangement profiling in solid tumors.
  • FoundationOne Tracker — Tissue-informed circulating-tumor-DNA test for treatment-response monitoring in advanced solid tumors.
  • GALEAS Bladder — Urine targeted NGS biomarker test used as a molecular triage and diagnostic aid for bladder cancer.
  • Galleri — Prescription-only multi-cancer early detection test.
  • GASTROClear — Blood-based miRNA test for early detection of gastric cancer.
  • GeneDx Comprehensive Common Cancer Panel — 49-gene germline hereditary-cancer panel (test code B275) using sequencing and deletion/duplication analysis.
  • GeneseeqPrime — FDA-cleared next-generation sequencing tumor-profiling assay for FFPE solid-tumor tissue.
  • GenMineTOP Cancer Genome Profiling System — Japanese tumor-normal DNA/RNA comprehensive genomic profiling system for solid tumors.
  • Guardant Reveal — Tissue-free ctDNA MRD/recurrence and therapy-response monitoring test with current methylation-focused commercial lineage.
  • Guardant360 Liquid CDx — Plasma cfDNA comprehensive genomic profiling and indication-specific companion diagnostic.
  • Guardant360 Tissue — Tissue-based multiomic comprehensive profiling for advanced solid tumors.
  • Haystack MRD — Tumor-informed ctDNA molecular residual disease assay for solid tumors using WES-derived personalized panels tracking up to 50 variants.
  • Idylla BRAF Mutation Test — European CE-IVD cartridge-based qPCR test for BRAF codon-600 mutations in melanoma.
  • Idylla EGFR Mutation Test — European CE-IVD/IVDR cartridge-based qPCR test for EGFR mutations in non-small cell lung cancer.
  • Idylla GeneFusion Panel — European CE-IVD qPCR panel for ALK, ROS1, RET and MET exon 14 molecular testing in non-small cell lung cancer.
  • Idylla KRAS Mutation Test — European CE-IVD cartridge-based qPCR test for KRAS mutations in colorectal cancer.
  • Idylla MSI Test — Microsatellite-instability molecular diagnostic test for colorectal cancer with jurisdiction-specific IVD/CDx versions.
  • Idylla NRAS-BRAF Mutation Test — European CE-IVD cartridge-based qPCR test for NRAS and BRAF mutations in colorectal cancer.
  • Invitae Common Hereditary Cancers Panel — NGS germline panel for common hereditary cancer predisposition.
  • Invitae Hereditary Breast and Gyn Cancers Panel — NGS germline panel for hereditary breast and gynecologic cancer predisposition.
  • Invitae Hereditary Breast Cancer STAT Panel — Time-sensitive germline hereditary breast-cancer STAT panel, Labcorp test 898053.
  • Invitae Hereditary Colorectal Cancer Guidelines-based Panel — NGS germline panel for hereditary colorectal cancer predisposition.
  • Invitae Hereditary Pancreatic Cancer Panel — NGS germline panel for hereditary pancreatic cancer predisposition.
  • Invitae Hereditary Prostate Cancer Panel — NGS germline panel for hereditary prostate cancer predisposition.
  • Invitae Multi-Cancer Panel — Current Labcorp Invitae germline multi-cancer hereditary-susceptibility panel, test 898041.
  • Invitae Personalized Cancer Monitoring — Tumor-informed personalized ctDNA monitoring assay for solid tumors.
  • ipsogen BCR-ABL1 mbcr Kit CE — CE-IVD real-time PCR kit for p190 BCR-ABL1 transcript quantification in B-cell acute lymphoblastic leukemia.
  • ipsogen BCR-ABL1 Mbcr Kit CE — CE-IVD real-time PCR kit for p210 BCR-ABL1 transcript quantification in hematologic malignancies.
  • ipsogen JAK2 RGQ PCR Kit — Real-time PCR assay detecting JAK2 V617F in whole blood as an adjunct in evaluation of suspected myeloproliferative neoplasms.
  • K-4CARE — Integrated genomic and transcriptomic profiling with ctDNA MRD monitoring for precision oncology.
  • Labcorp Plasma Complete — 521-gene plasma comprehensive genomic profiling LDT for advanced or metastatic solid tumors.
  • Labcorp Plasma Detect Genome MRD — Tumor-informed whole-genome sequencing ctDNA MRD test currently offered for stage III colon cancer baseline and monitoring.
  • LeukoStrat CDx FLT3 Mutation Assay — PCR and capillary-electrophoresis companion diagnostic for FLT3 ITD and TKD mutations in acute myeloid leukemia.
  • LiquidHALLMARK — Prescription plasma liquid-biopsy assay detecting ctDNA and ctRNA for molecular profiling and treatment selection in advanced cancer.
  • LucenceINSIGHT — Prescription blood-based multi-cancer early detection family using ctDNA and viral DNA with machine-learning tissue localization.
  • LUNGClear — Blood-based miRNA test for early detection of lung cancer.
  • LymphoVista — ctDNA sequencing in-house IVD for lymphoma genotyping, MRD assessment and longitudinal monitoring.
  • MammaPrint — 70-gene breast-cancer genomic risk classifier with multiple historical/current platform configurations that must remain version scoped.
  • Merlin CP-GEP — Clinicopathologic gene-expression profile used to stratify sentinel-lymph-node positivity risk in early cutaneous melanoma.
  • MI Cancer Seek — FDA-approved tissue NGS comprehensive tumor-profiling and companion-diagnostic device within the Caris MI Profile platform.
  • MI Profile — Caris tissue comprehensive molecular profiling service integrating WES, WTS, protein biomarkers and selected AI signatures for solid tumors.
  • MRDVision — Tumor-informed whole-genome MRD assay using a baseline tumor/normal genome and serial blood-based ctDNA monitoring.
  • MSK-ACCESS — Institutional ultra-deep cfDNA sequencing assay for noninvasive genomic profiling and disease monitoring; current panel covers 146 genes.
  • MSK-IMPACT — Tumor-normal targeted DNA sequencing for comprehensive tumor profiling.
  • MyChoice CDx — NGS-based homologous recombination deficiency companion diagnostic assessing BRCA1/2 and genomic instability in FFPE ovarian tumor tissue.
  • MyPath Melanoma — 23-gene qRT-PCR expression classifier for ambiguous melanocytic lesions.
  • MyRisk — Germline hereditary-cancer panel; current documented configuration contains 63 clinically recommended genes and must not inherit analytical metrics from historical 25-gene validation.
  • NavDx — Blood-based TTMV-HPV DNA laboratory-developed test used in HPV-driven cancer management and post-treatment recurrence surveillance.
  • Neo Comprehensive - Myeloid Disorders — 164-gene DNA/RNA clinical assay for molecular evaluation of myeloid neoplasms.
  • NEO PanTracer LBx — 514-gene ctDNA liquid-biopsy comprehensive genomic profiling assay for advanced pan-solid tumors, including MSI-H and bTMB.
  • NEO PanTracer Pro — 517-gene DNA and 55-gene RNA comprehensive genomic profiling test for solid tumors.
  • NEO PanTracer Tissue — 517-gene DNA/RNA tissue comprehensive genomic profiling for solid tumors.
  • NeoTYPE Precision Profile for Solid Tumors — Commercial solid-tumor molecular profiling panel combining targeted NGS with IHC and reflex assays to support treatment selection.
  • NeXT Personal Dx — Tumor-informed personalized ctDNA LDT using WGS-derived patient-specific signatures for MRD, recurrence and treatment-response monitoring.
  • Nodify CDT — Blood autoantibody classifier that raises malignancy risk for selected pulmonary nodules.
  • Nodify XL2 — Blood-based proteomic classifier to identify lung nodules likely benign.
  • Northstar Response — Tissue-free methylated-ctDNA liquid biopsy for quantitative treatment-response monitoring across advanced solid tumors.
  • Northstar Select — 102-gene plasma ctDNA comprehensive genomic profiling assay for therapy selection in advanced solid tumors.
  • OmniSeq INSIGHT — 523-gene DNA and 55-gene RNA clinical profiling test for solid tumors, with ancillary immune profiling.
  • OncoBEAM RAS CRC Kit CE-IVD — CE-IVD plasma ctDNA assay for detection of KRAS and NRAS mutations in colorectal cancer using BEAMing technology.
  • OncoDEEP — European comprehensive profiling solution integrating DNA, RNA and protein biomarkers from tumor samples for precision oncology.
  • Oncodetect MRD — Tumor-informed ctDNA molecular residual disease test used across solid tumors; current commercial configuration tracks up to 200 tumor-specific variants.
  • OncoExTra — Whole-exome and whole-transcriptome tumor profiling with matched-normal subtraction for advanced solid tumors.
  • Oncoguard Liver — Blood-based aid for HCC detection in an at-risk surveillance population.
  • OncoGuide EpiLight Methylation Detection Kit — Real-time PCR epigenomic assay measuring DNA methylation across 16 regions to support treatment selection in colorectal cancer.
  • OncoGuide NCC Oncopanel System — Japanese tumor-normal comprehensive genomic profiling system for solid tumors, with current Version 3 coverage of 124 cancer-related genes and a biliary companion-diagnostic function.
  • OncoGuide OncoScreen Plus CDx System — Japan-approved NGS companion diagnostic system for PIK3CA, AKT1 and PTEN alterations in defined breast cancer treatment selection.
  • OncoGuide PlasmaSeq Oncopanel System — Plasma ctDNA targeted sequencing assay for RAS and BRAF V600E alterations used to support treatment selection in colorectal cancer in Japan.
  • Oncomine Dx Express Test — FDA-approved rapid targeted NGS tumor profiling and companion diagnostic test.
  • Oncomine Dx Target Test — FDA-approved targeted NGS oncology companion diagnostic platform.
  • OncoSeek — Blood-based multi-cancer diagnostic-aid test combining seven protein tumor markers with age and sex in an AI model that reports cancer probability and likely tissue of origin.
  • Oncotype DX Breast Recurrence Score — 21-gene tumor RNA expression assay used in HR-positive, HER2-negative early breast cancer to estimate recurrence risk and inform potential chemotherapy benefit.
  • Oncuria — Ten-protein urine multiplex immunoassay for bladder-cancer diagnostic, recurrence-monitoring and response-prediction contexts.
  • OneTest for Cancer — Blood-based multi-cancer early detection LDT combining multiple serum tumor biomarkers with a machine-learning risk algorithm.
  • OverC Multi-Cancer Detection — Blood-based cfDNA methylation multi-cancer early detection test with six-cancer current product scope; jurisdiction-specific regulatory status.
  • PanTum Detect — Whole-blood multi-cancer screening aid detecting Apo10/DNaseX and TKTL1 signals in monocytes using EDIM/flow-cytometry-based methodology.
  • PathVysion HER-2 DNA Probe Kit — U.S. in vitro FISH assay for HER2 amplification assessment in breast cancer tissue.
  • PGDx elio plasma focus Dx — FDA-authorized plasma cfDNA next-generation sequencing tumor-profiling test for patients already diagnosed with solid malignant neoplasms.
  • PGDx elio tissue complete CDx — FDA-approved hybrid-capture NGS companion diagnostic on FFPE tumor tissue; current CDx scope includes melanoma BRAF V600E/V600K.
  • Precise MRD — Tumor-informed whole-genome sequencing MRD assay tracking up to 1,000 patient-specific variants for treatment and recurrence monitoring.
  • PredicineCARE — CLIA-certified 200-gene cfDNA assay for treatment selection and comprehensive molecular profiling in solid tumors.
  • Prolaris + AI — Prostate cancer prognostic/treatment-guidance test combining molecular score with clinical/pathology and AI.
  • Prosigna — PAM50/ROR breast-cancer prognostic classifier; historical FDA-cleared nCounter IVD and current US NGS LDT are distinct configurations.
  • Prostate Health Index (phi) — Serum p2PSA, total PSA and free PSA index used as an aid in distinguishing prostate cancer from benign prostatic conditions in the FDA-approved population.
  • ProVue Lung — Proteomics-based blood LDT designed to complement LDCT lung-cancer screening in high-risk adults.
  • QuantideX qPCR BCR-ABL IS Kit — RT-qPCR BCR-ABL1 monitoring kit standardized to the International Scale for chronic myeloid leukemia treatment-response assessment.
  • Quest Comprehensive Hereditary Cancer Panel — 66-gene germline panel for broad hereditary cancer susceptibility, Quest test code 38600.
  • Quest Guideline-Based Hereditary Cancer Panel — 32-gene germline hereditary cancer panel, Quest test code 38611.
  • Quest Hereditary Breast Cancer Panel — 18-gene germline panel for hereditary breast-cancer susceptibility, Quest test code 38621.
  • Quest Hereditary Colorectal Cancer Panel — 20-gene germline panel for hereditary colorectal-cancer susceptibility, Quest test code 38631.
  • RaDaR ST — Personalized tumor-informed ctDNA MRD assay for solid tumors; current ST generation uses WES tumor profiling and tracks up to 48 patient-specific mutations.
  • RadTox — Clinical cfDNA-concentration assay for treatment-response and progression monitoring in solid tumors.
  • Shield — Blood-based colorectal cancer screening test.
  • Signatera — Personalized tumor-informed circulating tumor DNA molecular residual disease test family. Includes the FDA-authorized Signatera CDx MIBC companion-diagnostic configuration and broader laboratory-developed clinical uses that remain separately scoped.
  • SimpleScreen CRC — FDA-approved blood-based colorectal cancer screening test for average-risk adults age 45 and older.
  • SimpleScreen Lung — Blood-based multiomic LDT intended to increase lung-cancer screening participation among eligible high-risk adults not completing LDCT.
  • SPOT-MAS 10 — Blood-based multi-cancer screening test using cfDNA methylation and fragmentomic signals with machine learning.
  • SPOT-MAS CRC — Plasma SEPTIN9 DNA methylation test for colorectal cancer early detection.
  • SPOT-MAS Lung — Plasma multi-omic cfDNA test for early detection of lung cancer.
  • Stockholm3 — Blood-based prostate cancer risk test integrating PSA, additional proteins, a polygenic risk score and clinical variables.
  • Tempus DPYD — Single-gene germline pharmacogenomic test for DPYD-associated fluoropyrimidine toxicity risk.
  • Tempus HRD — Algorithmic laboratory-developed homologous recombination deficiency assessment using cancer-specific DNA or RNA implementations.
  • Tempus IPS — Multi-omic algorithmic laboratory-developed test that generates an Immune Profile Score in metastatic or stage IV solid tumors.
  • Tempus PurIST — RNA-based algorithmic classifier of basal-like versus classical pancreatic ductal adenocarcinoma subtype.
  • Tempus TO — RNA-expression tumor-origin classifier for cancer of unknown or uncertain primary site.
  • Tempus UGT1A1 — Single-gene germline pharmacogenomic test for UGT1A1-associated anticancer-therapy toxicity risk.
  • Tempus xE — Whole-exome tumor DNA sequencing test covering more than 19,000 genes in solid tumors.
  • Tempus xF — 105-gene plasma liquid-biopsy genomic profiling test for solid tumors.
  • Tempus xF+ — 523-gene plasma liquid-biopsy comprehensive genomic profiling assay for therapy selection and molecular profiling in advanced cancer.
  • Tempus xM — Tumor-naive liquid-only MRD assay combining methylation- and variant-based workflows for stage II-III colorectal cancer.
  • Tempus xR — Whole-transcriptome RNA sequencing test for solid tumors and hematologic neoplasms.
  • Tempus xT CDx — 648-gene tissue comprehensive genomic profiling companion diagnostic.
  • Tempus xT Heme — 648-gene DNA sequencing configuration for hematologic neoplasms.
  • therascreen BRAF V600E RGQ PCR Kit — Real-time PCR companion diagnostic for source-scoped BRAF V600E testing in colorectal cancer.
  • therascreen EGFR RGQ PCR Kit — FDA-approved real-time PCR companion diagnostic for EGFR mutation testing in non-small cell lung cancer.
  • therascreen FGFR RGQ RT-PCR Kit — RNA-based real-time PCR companion diagnostic for source-scoped FGFR3 alteration testing in urothelial cancer.
  • therascreen KRAS RGQ PCR Kit — FDA-approved real-time PCR KRAS companion diagnostic for colorectal cancer.
  • therascreen PIK3CA RGQ PCR Kit — FDA-approved real-time PCR PIK3CA companion diagnostic for breast cancer.
  • ThyGeNEXT + ThyraMIR v2 — Combined NGS mutation/fusion and microRNA classifier workflow for indeterminate thyroid nodules.
  • ThyroSeq Genomic Classifier — Molecular genomic classifier for indeterminate thyroid nodules.
  • Trucheck Intelli — Blood-based multi-cancer early detection test that detects circulating tumor cells and reports likely tissue/tumor context across many solid tumors.
  • TruSight Oncology Comprehensive — DNA/RNA comprehensive genomic profiling assay for solid tumors with indication-specific companion-diagnostic claims.
  • UriFind — Urine ONECUT2/VIM DNA methylation test used as an auxiliary diagnostic aid for suspected urothelial cancer.
  • UroVysion Bladder Cancer Kit — U.S. urine FISH assay used as a diagnostic aid and for recurrence surveillance in bladder cancer.
  • Vysis ALK Break Apart FISH Probe Kit — U.S. in vitro FISH assay for ALK rearrangement testing in non-small cell lung cancer.
  • Vysis CLL FISH Probe Kit — U.S. peripheral-blood FISH assay for prognostic and source-scoped therapy-selection contexts in chronic lymphocytic leukemia.
  • Xpert BCR-ABL Ultra — Automated quantitative molecular test for BCR::ABL1 major-breakpoint transcripts used for chronic myeloid leukemia monitoring.
  • Xpert NPM1 Mutation — Automated RT-qPCR assay for quantitative monitoring of NPM1-mutated acute myeloid leukemia in CE-IVD markets.